IMA

Rating neutralAI Memo

ImageneBio

As of 2026-10-02/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

ADAPTIVE Phase 2b atopic dermatitis topline • 2027-12-31

Base target: $4 / p=45% prob

Biggest risk

IMA remains concentrated in olevaprubart. An amended study design, delayed or unfavorable data, higher development spending, or another dilutive financing could overwhelm the apparent cash-versus-market-cap discount. The deterministic prior is negative despite strong primary-source coverage.

Invalidation

Break below $2 or thesis failure.

What would change my mind?

The August company update reported ADAPTIVE progressing under its amended protocol, a planned second Phase 2 program, and a runway expected to extend into early 2028. Favorable clinical data could materially revalue a roughly $52 million equity, but the pivotal evidence remains future-dated [#SEC-8K-2026-08-05].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-02

Base target

p=45%

Bull target

p=20%

Bear target

p=35%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Planned Phase 2 alopecia areata trial initiation
Runway versus the clinical timetable
The August company update reported ADAPTIVE progressing under its amended protocol, a planned second Phase 2 program, and a runway expected to extend into early 2028.

BearKey bullets

ADAPTIVE efficacy and safety remain unproven; the principal topline readout is not expected until fourth-quarter 2027 [#SEC-8K-2026-08-05].
Quarterly R&D expense rose to $6.7 million from $5.7 million a year earlier, while G&A rose to $5.1 million from $1.7 million; spending or schedule changes could shorten the stated runway [#PR-EARNINGS-2026-08-05].
The April 2026 private placement provided capital but illustrates dilution risk [#SEC-8K-2026-08-05].

WatchKey bullets

ADAPTIVE Phase 2b atopic dermatitis topline

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $4 (p=45%)

Target spread vs base: +137% / -61%

Scenario probabilities

Bull Target: $9 (p=20%)Base Target: $4 (p=45%)Bear Target: $2 (p=35%)

Commentary

Cautious monitoring view. The packet contains strong company-source operating context but no recent news, validated analyst revisions, post-release price reaction, or sufficient social/options data; zero sentiment fields indicate unavailable measurements, not neutral observations. The deterministic score points negative despite higher evidence quality and catalyst density than the prior baseline. No new clinical result is established.

As of 2026-10-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Planned Phase 2 alopecia areata trial initiation
Runway versus the clinical timetable

Scenarios

Bull Target (Scenario probability)

$9 / p=20% prob

Base Target (Scenario probability)

$4 / p=45% prob

Bear Target (Scenario probability)

$2 / p=35% prob

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-12-31
ADAPTIVE Phase 2b atopic dermatitis topline
The company anticipated fourth-quarter 2027 topline data from the amended Phase 2b ADAPTIVE study. Its August release said the study was progressing and that an independent monitoring committee recommended continuing without changes in July; neither establishes efficacy. This is the principal clinical value inflection [#SEC-8K-2026-08-05].
Prob 60.00% • Move 45.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

Planned Phase 2 alopecia areata trial initiation
2026-12-31
ImageneBio planned to initiate a Phase 2 olevaprubart trial in alopecia areata during 2026. Initiation would confirm execution of the expanded development plan, but the August update projected initial data only in 2028; trial start is not an efficacy readout. The plan appears in the company release furnished with its August 5 8-K [#8-K-2026-08-05] [#SEC-8K-2026-08-05].
Prob 65% • Move 8% • Priced-in 55%

Long-term Catalysts

Months to a year

Runway versus the clinical timetable
2028-03-31
ImageneBio reported $136.2 million of cash, cash equivalents and marketable securities at June 30, 2026, after an April private placement, and expected funding for planned operations into the first quarter of 2028. Spending, trial timing or additional financing could change that outlook; the runway is a monitoring point, not proof that development will be completed without dilution [#SEC-8K-2026-08-05].
Prob 65% • Move 10% • Priced-in 70%

Risks

ADAPTIVE efficacy and safety remain unproven; the principal topline readout is not expected until fourth-quarter 2027 [#SEC-8K-2026-08-05].
Quarterly R&D expense rose to $6.7 million from $5.7 million a year earlier, while G&A rose to $5.1 million from $1.7 million; spending or schedule changes could shorten the stated runway [#PR-EARNINGS-2026-08-05].
The April 2026 private placement provided capital but illustrates dilution risk [#SEC-8K-2026-08-05].
The planned alopecia areata Phase 2 study adds R&D demands, with initial data projected for 2028 [#SEC-8K-2026-08-05].

Peers

Symbol	Summary
INMB	Packet-selected similar-market-cap biotech with unverified clinical and indication overlap; a loose risk comparator, not a direct peer.
ANVS	Packet-selected similar-market-cap clinical biotech, but not a verified same-indication or same-mechanism peer; useful only for financing and event-volatility context.
ELTX	Packet-selected similar-market-cap biotech. No direct operating comparability was established, so its valuation should not anchor IMA.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-02

Loading AI feed…

Symbol

Summary

INMB

Packet-selected similar-market-cap biotech with unverified clinical and indication overlap; a loose risk comparator, not a direct peer.

ANVS

Packet-selected similar-market-cap clinical biotech, but not a verified same-indication or same-mechanism peer; useful only for financing and event-volatility context.

ELTX

Packet-selected similar-market-cap biotech. No direct operating comparability was established, so its valuation should not anchor IMA.